JAGSNPHARM Jagsonpal Pharmaceuticals Q1 FY26 results (Apr–Jun 2025) and concall
Jagsonpal Pharma reported a strong Q1 FY26 with significant revenue and profit growth, driven by brand equity and operational discipline. Despite the termination of its CFO and pricing pressure on a key molecule, the company maintained robust margins and increased its cash balance, reinforcing its ability to pursue organic and inorganic growth strategies. Management reiterated its annual growth and margin expansion guidance, expecting improvements from Q2 onwards.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 75 | 74 | 59 | 76 |
| EBITDA | 16 | 16 | 9 | 14 |
| Net profit | 11 | 32 | 7 | 11 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
